High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure
Status:
Withdrawn
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Prospective, open-label, randomized cohort study comparing adding high-dose spironolactone to
usual heart failure care versus usual care in patients with acute decompensated heart
failure. Patients will be randomized in a 1:1 fashion to either usual care or high-dose
spironolactone plus usual care. Both arms of the study will continue with treatment of ADHF
until euvolemia as defined as the resolution of pulmonary edema, peripheral edema, abdominal
bloating and/or jugular venous distention. Assessment of clinical status and serum
electrolytes, symptoms and renal function will be performed in accordance to standard of
care.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio